ORTEXORTEX News
Tracking CAPR? Get live short interest, options flow, and signals on ORTEX.Sign up free →
CA

Capricor Therapeutics, Inc. (CAPR) short interest & options flow

NASDAQ

CAPR enters the final stretch before the November 22 FDA decision on deramiocel carrying nearly 40% short interest, a sharply rising put/call ratio, and two institutional holders who have just exited entirely. Short interest has pulled back from its late-October peak but remains extreme. At 39.9% of the free float, the bearish position is down 13% on the week as some shorts trimmed…

Latest pulse6d ago

CAPR upgraded to Buy by Jones Trading with $25 price target, up from Hold rating. Stock at $10.24, down 8.7% today but up 37% over one month ahead of FDA decision on deramiocel November 22.

$8.03-4.52% 1d-28.43% 1w+19.67% 1mClose: 18 Nov 2026
Short interest % of float
High
Live SI on ORTEX →
Availability
Low
Live availability on ORTEX →
Market cap
$489M
Next earnings
15 Mar 2027
See the full picture on ORTEX →Live short interest, options flow, signals, 13F filings, and more.

Key data as of 20 Nov 2026

ORTEX chart of Capricor Therapeutics, Inc. (CAPR) share price and short interest (% of free float), six months to November 18, 2026

Latest signals on CAPR

  • Analyst

    CAPR upgraded to Buy by Jones Trading with $25 price target, up from Hold rating. Stock at $10.24, down 8.7% today but up 37% over one month ahead of FDA decision on deramiocel November 22.